Dr. Grupp on the Optimal Setting of CAR T-Cell Therapy in ALL

Video

Stephan Grupp, MD, PhD, director, Cancer Immunotherapy Program, director, Translational Research for the Center for Childhood Cancer Research, medical director, Stem Cell Laboratory, Children’s Hospital of Philadelphia, discusses the placement of chimeric antigen receptor (CAR) T-cell therapy in the treatment of patients with acute lymphoblastic leukemia (ALL).

Stephan Grupp, MD, PhD, director, Cancer Immunotherapy Program, director, Translational Research for the Center for Childhood Cancer Research, medical director, Stem Cell Laboratory, Children’s Hospital of Philadelphia, discusses the placement of chimeric antigen receptor (CAR) T-cell therapy in the treatment of patients with acute lymphoblastic leukemia (ALL).

Currently, the CAR T-cell therapy tisagenlecleucel (Kymriah) has been approved by the FDA for the treatment of pediatric and young adult patients with relapsed or refractory ALL; however, physicians are hoping to bring it into earlier lines of therapy. In the past 5 or 6 years, referring physicians have been calling specialists earlier, notes Grupp. Patients who are referred early often have a lower disease burden, he adds.

The Children's Oncology Group is set to launch an international study to evaluate whether CAR T-cell therapy can be used as frontline therapy in patients who have not relapsed; these are high-risk patients who still have minimal residual disease after receiving 2 cycles of chemotherapy. Earlier introduction of CAR T-cell therapy may obviate the need for transplant, explains Grupp. The trial is set to open in the next month or two.

Related Videos
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
© 2024 MJH Life Sciences

All rights reserved.